Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: An in vitro study

Brain Research

Volumn 1294, Issue , 2009, Pages 144-152

  Culot, Maxime ^a,b   Mysiorek, Caroline ^a,b   Renftel, Mila ^c   Roussel, Benoit D ^d   Hommet, Yannick ^d   Vivien, Denis ^d   Cecchelli, Roméo ^a,b   Fenart, Laurence ^a,b   Berezowski, Vincent ^a,b   Dehouck, Marie Pierre ^a,b   Lundquist, Stefan ^c  

^a UNIV LILLE   (France)

^b EA 2465   (France)

^c ASTRAZENECA R AND D   (Sweden)

^d INSERM   (France)

Author keywords

Blood brain barrier; Endothelium; Ischemia; Neuroprotection; NXY 059; Stroke

Indexed keywords

DISUFENTON SODIUM; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SUCROSE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN ISCHEMIA; BRAIN PROTECTION; COW; ENDOTHELIUM CELL; GLIA CELL; HYPOXIA; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 70249144274     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.07.035     Document Type: Article

References (35)

1. Benchenane K., Lopez-Atalaya J.P., Fernandez-Monreal M., Touzani O., and Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27 (2004) 155-160
2. Benchenane K., Berezowski V., Ali C., Fernandez-Monreal M., Lopez-Atalaya J.P., Brillault J., Chuquet J., Nouvelot A., MacKenzie E.T., Bu G., Cecchelli R., Touzani O., and Vivien D. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111 (2005) 2241-2249
3. Benchenane K., Berezowski V., Fernandez-Monreal M., Brillault J., Valable S., Dehouck M.P., Cecchelli R., Vivien D., Touzani O., and Ali C. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 36 (2005) 1065-1070
4. Booher J., and Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 2 (1972) 97-105
5. Brillault J., Berezowski V., Cecchelli R., and Dehouck M.P. Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood-brain barrier during ischaemia. J. Neurochem. 83 (2002) 807-817
6. Cecchelli R., Dehouck B., Descamps L., Fenart L., Buee-Scherrer V.V., Duhem C., Lundquist S., Rentfel M., Torpier G., and Dehouck M.P. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36 (1999) 165-178
7. Cecchelli R., Berezowski V., Lundquist S., Culot M., Renftel M., Dehouck M.P., and Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev., Drug Discov. 6 (2007) 650-661
8. Cipolla M.J., Crete R., Vitullo L., and Rix R.D. Transcellular transport as a mechanism of blood-brain barrier disruption during stroke. Front. Biosci. 9 (2004) 777-785
9. Culot M., Lundquist S., Vanuxeem D., Nion S., Landry C., Delplace Y., Dehouck M.P., Berezowski V., Fenart L., and Cecchelli R. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol. In Vitro 22 (2008) 799-811
10. Dehouck M.P., Meresse S., Delorme P., Fruchart J.C., and Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 54 (1990) 1798-1801
11. Dehouck M.P., Jolliet-Riant P., Bree F., Fruchart J.C., Cecchelli R., and Tillement J.P. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J. Neurochem. 58 (1992) 1790-1797
12. Dehouck M.P., Cecchelli R., Richard Green A., Renftel M., and Lundquist S. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res. 955 (2002) 229-235
13. del Zoppo G.J. Stroke and neurovascular protection. N. Engl. J. Med. 354 (2006) 553-555
14. Diener H.C., Lees K.R., Lyden P., Grotta J., Davalos A., Davis S.M., Shuaib A., Ashwood T., Wasiewski W., Alderfer V., Hardemark H.G., and Rodichok L. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39 (2008) 1751-1758
15. Fagan S.C., Hess D.C., Hohnadel E.J., Pollock D.M., and Ergul A. Targets for vascular protection after acute ischemic stroke. Stroke 35 (2004) 2220-2225
16. Green A.R., and Ashwood T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 109-118
17. Green A.R., and Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discov. Today 11 (2006) 681-693
18. Green A.R., Lanbeck-Vallen K., Ashwood T., Lundquist S., Lindstrom Boo E., Jonasson H., and Campbell M. Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. Brain Res. 1072 (2006) 224-226
19. Hainsworth A.H., Bhuiyan N., and Green A.R. The nitrone disodium 2,4-sulphophenyl-N-tert-butylnitrone is without cytoprotective effect on sodium nitroprusside-induced cell death in N1E-115 neuroblastoma cells in vitro. J. Cereb. Blood Flow Metab. 28 (2008) 24-28
20. Kaur C., Sivakumar V., Zhang Y., and Ling E.A. Hypoxia-induced astrocytic reaction and increased vascular permeability in the rat cerebellum. Glia 54 (2006) 826-839
21. Kuroda S., Tsuchidate R., Smith M.L., Maples K.R., and Siesjo B.K. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 19 (1999) 778-787
22. Lapchak P.A., Araujo D.M., Song D., Wei J., Purdy R., and Zivin J.A. Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 33 (2002) 1665-1670
23. Lapchak P.A., Araujo D.M., Song D., Wei J., and Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
24. Lapchak P.A., Song D., Wei J., and Zivin J.A. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. 188 (2004) 279-285
25. Lees K.R., Zivin J.A., Ashwood T., Davalos A., Davis S.M., Diener H.C., Grotta J., Lyden P., Shuaib A., Hardemark H.G., and Wasiewski W.W. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354 (2006) 588-600
26. Lundquist S., Renftel M., Brillault J., Fenart L., Cecchelli R., and Dehouck M.P. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm. Res. 19 (2002) 976-981
27. Maples K.R., Green A.R., and Floyd R.A. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs 18 (2004) 1071-1084
28. Marshall J.W., Cummings R.M., Bowes L.J., Ridley R.M., and Green A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34 (2003) 2228-2233
29. Michaud C.M., Murray C.J., and Bloom B.R. Burden of disease-implications for future research. JAMA 285 (2001) 535-539
30. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E.T., Vivien D., and Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7 (2001) 59-64
31. Plateel M., Dehouck M.P., Torpier G., Cecchelli R., and Teissier E. Hypoxia increases the susceptibility to oxidant stress and the permeability of the blood-brain barrier endothelial cell monolayer. J. Neurochem. 65 (1995) 2138-2145
32. Plateel M., Teissier E., and Cecchelli R. Hypoxia dramatically increases the nonspecific transport of blood-borne proteins to the brain. J. Neurochem. 68 (1997) 874-877
33. Rapoport S.I., and Robinson P.J. Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann. N.Y. Acad. Sci. 481 (1986) 250-267
34. Sydserff S.G., Borelli A.R., Green A.R., and Cross A.J. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. 135 (2002) 103-112
35. Yoshimoto T., Kanakaraj P., Ying Ma J., Cheng M., Kerr I., Malaiyandi L., Watson J.A., Siesjo B.K., and Maples K.R. NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res. 947 (2002) 191-198